Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC.
Cekay M, Arndt PF, Dumitrascu R, Savai R, Braeuninger A, Gattenloehner S, Steiner D, Roller F, Tello K, Hattar K, Seeger W, Sibelius U, Grimminger F, Eul B.
Cekay M, et al. Among authors: savai r.
Front Oncol. 2023 Aug 16;13:1182391. doi: 10.3389/fonc.2023.1182391. eCollection 2023.
Front Oncol. 2023.
PMID: 37655099
Free PMC article.